drugset / Trial / NCT02638428
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.
Timeline
- Start
- 2015-12
- Primary completion
- 2021-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | — | — |
| Subject | Crizotinib | Small molecule | — | — |
| Subject | Erlotinib | Small molecule | — | — |
| Subject | Everolimus | Small molecule | — | — |
| Subject | Imatinib | Small molecule | — | — |
| Subject | Pazopanib | Small molecule | — | — |
| Subject | Ruxolitinib | Small molecule | — | — |
| Subject | Sorafenib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |
| Subject | Vandetanib | Small molecule | — | — |
| Subject | Vemurafenib | Small molecule | — | — |
| Subject | dasatinib anhydrous | Small molecule | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |
| Background | Ifosfamide | Small molecule | — | — |